The Institute for Clinical and Economic Review (ICER) released a new report outlining a planned review of acute migraine treatments.
According to a press release, ICER is planning to assess the following treatments:
- Biohaven’s rimegepant;
- Allergan’s ubrogepant; and
- Eli Lilly’s agonist lasmiditan.
ICER is accepting comments on the draft scoping document. The deadline to submit feedback is 5 p.m. July 19.
An updated scoping document will be released around July 29.
To read the full press release, click here.